Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome

Trial Profile

Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Hypertension; Insulin resistance
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 03 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 03 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 18 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top